中奥生物医药技术

Sino-Austrian (Zhejiang) Biological Medicine Technology is a biopharmaceutical company specializing in the development of recombinant protein drugs and innovative vaccines. The company leverages a high-efficiency yeast expression system (Pichia pastoris) to produce animal-free recombinant human albumin, targeting large-scale clinical needs in critical care, hepatology, and surgery. Beyond its lead albumin program, the company is advancing a pipeline of recombinant vaccines for infectious diseases, including candidates for HPV and shingles. Headquartered in Huzhou, China, the firm focuses on bridging international biotechnological collaborations to deliver safer, high-purity alternatives to plasma-derived products. Their integrated approach spans from early-stage R&D to large-scale GMP manufacturing.